Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28360751 | 1.00 | CYP1A2 (0.50) | CYP1A2SIGMAR1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL608793 | 1.00 | CYP1A2 (0.50) | CYP1A2SIGMAR1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL7078699 | 0.98 | CYP1A2 (0.46) | CYP1A2SIGMAR1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL6318571 | 0.93 | SIGMAR1 (0.50) | CYP1A2SIGMAR1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL7398026 | 0.93 | SIGMAR1 (0.50) | CYP1A2SIGMAR1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL3938909 | 0.93 | — | — | |
| SCHEMBL28815681 | 0.91 | SIGMAR1 (0.54) | CYP1A2SIGMAR1TSHREPHX1GPR84 | |
| SCHEMBL1162323 | 0.91 | SIGMAR1 (0.54) | CYP1A2SIGMAR1TSHREPHX1GPR84 | |
| SCHEMBL9801592 | 0.91 | SIGMAR1 (0.54) | CYP1A2SIGMAR1TSHREPHX1GPR84 | |
| Bicarbonate SCHEMBL10341681 | 0.90 | CYP1A2 (0.42) | CYP1A2SIGMAR1EPHX1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082372-A1 | Arylmethylene Substituted N-Acyl-Beta-Amino Alcohols | BAYER SCHERING PHARMA AG (DE) | 2009-03-26 | — | — | US | disclosed |
| US-20090075987-A1 | ALKYLACETYLENE SUBSTITUTED ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| US-20090069321-A1 | CYANOMETHYL SUBSTITUTED N-ACYL TRYPTAMINES | BAYER SCHERING PHARMA AG (DE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069328-A1 | ALPHA-ALKYL SUBSTITUTED N-ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2009-03-12 | — | — | US | disclosed |
| WO-2009021980-A1 | α-ALKYL SUBSTITUTED N-ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-19 | — | — | WO | disclosed |
| EP-2025669-A1 | Alpha-alkyl substituted N-acyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2009016253-A2 | CYANOMETHYL SUBSTITUTED N-ACYL TRYPTAMINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-05 | — | — | WO | disclosed |
| EP-2020404-A1 | Cyanomethyl substituted N-Acyl Tryptamines | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-02-04 | — | — | EP | disclosed |
| WO-2009013333-A1 | ALKYLACETYLENE SUBSTITUTED ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-29 | — | — | WO | disclosed |
| WO-2009013354-A1 | ARYLMETHYLENE SUBSTITUTED N-ACYL-β-AMINO ALCOHOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-29 | — | — | WO | disclosed |
| WO-2008104597-A2 | SULFONYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | WO | disclosed |
| EP-1964834-A1 | Sulphonyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-09-03 | — | — | EP | disclosed |
| US-20080207728-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-08-28 | — | — | US | disclosed |
| EP-1956016-A1 | Bicyclic acyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-08-13 | — | — | EP | disclosed |
| WO-2008071453-A1 | 1,2-DIARYLACETYLENE DERIVATIVES OF ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008071455-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | disclosed |
| EP-1932831-A1 | 1,2-Diarylacetylene Derivatives of Acyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-06-18 | — | — | EP | disclosed |
| EP-1912970-A2 | ACYLTRYPTOPHANOLS FOR FERTILITY CONTROL | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-04-23 | — | — | EP | disclosed |
| US-20070060573-A1 | Acyltryptophanols | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-15 | — | — | US | disclosed |
| WO-2007017289-A2 | ACYLTRYPTOPHANOLS FOR FERTILITY CONTROL | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069328-A1 | ALPHA-ALKYL SUBSTITUTED N-ACYLTRYPTOPHANOLS | FSHR, GNRHR, TPH1 | CYP1A2 451/4885SIGMAR1 439/4885CHRNB2 242/4885 |
| US-20090069321-A1 | CYANOMETHYL SUBSTITUTED N-ACYL TRYPTAMINES | FSHR, GNRHR, HNMT | CYP1A2 1394/4885SIGMAR1 1099/4885CHRNB2 289/4885 |
| US-20080207728-A1 | BICYCLIC ACYLTRYPTOPHANOLS | FSHR, GNRHR, TPH1 | CYP1A2 446/4885SIGMAR1 409/4885CHRNB2 370/4885 |
| US-20070060573-A1 | Acyltryptophanols | FSHR, NPY1R, NPY2R | CYP1A2 684/4885SIGMAR1 668/4885CHRNB2 419/4885 |
| US-20090075987-A1 | ALKYLACETYLENE SUBSTITUTED ACYLTRYPTOPHANOLS | FSHR, GNRHR, CYP19A1 | CYP1A2 396/4885SIGMAR1 906/4885CHRNB2 279/4885 |
| US-20090082372-A1 | Arylmethylene Substituted N-Acyl-Beta-Amino Alcohols | FSHR, SHBG, NAT1 | CYP1A2 340/4885SIGMAR1 989/4885CHRNB2 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.